US Bancorp
GLUE icon

US Bancorp’s Monte Rosa Therapeutics GLUE Stock Holding History

US Bancorp’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$197 Buy
+12
New +$229 ﹤0.01% 4102
2025
Q1 		– Sell
-26
Closed -$180 – 4268
2024
Q4 		$180 Buy
+26
New +$195 ﹤0.01% 4088

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

US Bancorp's GLUE Position: Q1 2026 in Review

US Bancorp opened a new position in Monte Rosa Therapeutics (GLUE) in Q1 2026: 12 shares worth $197. The stake represents ﹤0.01% of the portfolio and ranks #4102 among its holdings. This is a return to the name: US Bancorp previously reported a position in GLUE as recently as Q4 2024.

US Bancorp first reported a position in GLUE in Q4 2024 and has held it in 2 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • US Bancorp held 12 shares of Monte Rosa Therapeutics worth $197 as of Q1 2026.
  • Monte Rosa Therapeutics was a new US Bancorp position in Q1 2026.
  • Monte Rosa Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #4102 holding.
  • US Bancorp first reported a position in Monte Rosa Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.